Cencora, Inc.

Cencora, Inc.

COR

$339.76

Updated: 03/11/2026, 18:34:33

Market Cap
$64.85B
Sector
Healthcare
Industry
Medical - Distribution
Country
US

No historical data available

Company Profile

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

USD
NYSE
CEO: Robert Mauch
Employees: 49,000
https://www.cencora.com
Asset Summaries
Latest generated summaries for COR

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
COR-10-k-fy2025.html2.0 MBtext/htmlENFiled 25/11/2025Period ended 30/09/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 46 KPI observations

Revenue

N/A

FY — · Reported

Net income

$1.6B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$3.2B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$0.4B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Top products and services
Products and services mentioned in the filing; a quantitative sales breakdown was not disclosed.

Other offerings mentioned without separate sales

Value-added services
U.S. Healthcare Solutions offerings
International Healthcare Solutions offerings
Provider solutions programs

Area-level product sales are displayed only when the filing reports a product × geography breakdown. Regional totals are not allocated across products by estimation.

Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Company overview

Global pharmaceutical sourcing and distribution services company serving healthcare providers and pharma/biotech manufacturers

99%
Source evidence
“Cencora is one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.”

Business overview

Global pharmaceutical sourcing and distribution services company in human and animal health

98%
Source evidence
“We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care.”

Reportable segments

Two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions

99%
Source evidence
“we report our results under two reportable segments: U.S. Healthcare Solutions and International Healthcare Solutions.”

Reportable segments and new structure

Two reportable segments; from Q1 FY2026: U.S. Healthcare Solutions, International Healthcare Solutions, and Other

95%
Source evidence
“Beginning in the first quarter of fiscal 2026, our reporting structure will be comprised of U.S. Healthcare Solutions, International Healthcare Solutions, and Other.”

Customer types served

Hospitals/health systems, retail and mail order pharmacies, physician practices, dialysis clinics, long-term care, veterinarians

98%
Source evidence
“including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, physician practices, medical and dialysis clinics, veterinarians, and other customers.”

Provider customers reimbursed under Medicare Part B

Specialty drug sales to hospitals, specialty community physician practices (oncology, retina specialists) and other Medicare Part B-reimbursed providers; recent physician specialty network investments/acquisitions exposed to CMS ASP/BFSF changes.

90%
Source evidence
“our businesses also sell specialty and other drugs to hospitals, specialty community physician practices (including oncology and retina specialists), and other providers that are reimbursed under Part B of the Medicare program”

Value-added services

Provider and manufacturer services including consulting, logistics, pharmacy automation, and packaging

97%
Source evidence
“including data analytics, outcomes research, reimbursement and pharmaceutical consulting services (including regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance) niche premium logistics services, inventory management, pharmacy automation, pharmacy management, and packaging solutions.”

U.S. Healthcare Solutions offerings

Comprehensive U.S. pharma distribution plus specialty, pharmacy services, packaging, animal health, and manufacturer sales-force services

97%
Source evidence
“The U.S. Healthcare Solutions reportable segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services”

International Healthcare Solutions offerings

International wholesale, biopharma specialty logistics, and life-sciences commercialization services

96%
Source evidence
“It is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. It is also a provider of specialized services, including regulatory affairs, market access, pharmacovigilance, development consulting and scientific affairs, and quality management and compliance, for the life sciences industry.”

Provider solutions programs

Good Neighbor Pharmacy®, Elevate Provider Network®, generics private label program (Ireland-based), hospital pharmacy consulting

95%
Source evidence
“our Good Neighbor Pharmacy® program, which enables independent community pharmacies to compete more effectively through pharmaceutical benefit and merchandising programs; Elevate Provider Network®, our managed care network... and is one of the largest in the United States”

Segment revenue FY2025 vs FY2024 vs FY2023

FY2025 revenue $321.33B (U.S. Healthcare Solutions $290.98B, incl. Human Health $285.29B / Animal Health $5.69B; International $30.37B, incl. Alliance Healthcare $24.39B); FY2024 $293.96B; FY2023 $262.17B

99%
Source evidence
“Revenue$321,332,819 $293,958,599 $262,173,411”

Positioning and strategy

Retina Consultants of America acquisition

Acquired 85% of RCA on Jan 2, 2025 for $4,042.0M cash plus contingent consideration totaling ~$1,087.5M

98%
Source evidence
“On January 2, 2025, we acquired an 85% interest in Retina Consultants of America (“RCA”) for $4,042.0 million in cash”

OneOncology investment

$718.4M investment for 34.9% interest in joint venture acquiring OneOncology

97%
Source evidence
“In June 2023, we invested $718.4 million (representing a 34.9% interest) in a joint venture to acquire OneOncology, a network of leading oncology practices, with TPG Inc., a global alternative asset management firm, holding the majority interest in the joint venture.”

RCA acquisition (January 2025)

January 2025 acquisition of RCA boosted U.S. gross profit (+$1,482.3M, +23.1%) and operating expenses

95%
Source evidence
“U.S. Healthcare Solutions’ gross profit increased by $1,482.3 million, or 23.1%, from the prior fiscal year primarily due to increased sales and the January 2025 acquisition of RCA.”

GLP-1 product growth

GLP-1 (diabetes/weight loss) sales increased $7.7B, or 26.9%, in fiscal 2025

98%
Source evidence
“increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class of $7.7 billion, or 26.9%.”

Specialty distribution leadership

Leader in specialty distribution to health systems, community oncologists, retina specialists

94%
Source evidence
“We are a leader in distribution and services to health systems, community oncologists, and retina specialists and have leading positions in other physician-administered products.”

Risks, financing, and outlook

WBA distribution and generics agreements

Walgreens/WBAD agreements run to 2029, Boots to 2031; WBA now owned by Sycamore Partners

97%
Source evidence
“On August 28, 2025, Sycamore Partners, a private equity firm, acquired Walgreens Boots Alliance, Inc. (“WBA”).”

U.S. pharma market growth expectation

U.S. pharmaceutical sales expected to grow ~8.4% CAGR 2024-2029 per IQVIA

94%
Source evidence
“Pharmaceutical sales in the United States, as recently estimated by IQVIA, an independent third-party provider of information to the pharmaceutical and healthcare industry, are expected to grow at a compound annual growth rate of approximately 8.4% from 2024 through 2029”

CMS 340B retrospective refund rule and proposed acceleration

CMS 340B refund rule: ~$9B refunds to 340B hospitals; 0.5% Medicare outpatient payment cuts CY2026-2040; July 2025 proposal raises cut to 2.0% (10-year acceleration) plus 340B acquisition-cost survey.

95%
Source evidence
“lump-sum refund payments totaling approximately $9 billion to be made to affected 340B hospitals and requires budget neutrality for the hospital outpatient payment system as a whole, reducing Medicare payments to all hospitals for other hospital outpatient services by 0.5% for calendar years 2026-2040”

OBBBA (July 2025) Medicaid/ACA provisions

OBBBA (July 2025): Medicaid work requirements/cost-sharing, Medicare provider payment cuts, tightened ACA exchange subsidy eligibility — may hurt customer financial stability and product demand.

93%
Source evidence
“implements work requirements for certain Medicaid patients to maintain eligibility and expands cost-sharing for certain Medicaid-eligible individuals”

340B contract pharmacy disputes

Manufacturers limit contract pharmacy arrangements under 340B and may not honor chargebacks; HRSA stopped challenging these policies; multiple states passed related legislation.

93%
Source evidence
“numerous manufacturers announced initiatives that inhibit or limit covered entities' ability to use any, or multiple, contract pharmacies”

CMS October 2025 ASP/bona fide service fee rule

CMS final rule (Oct 2025) tightens BFSF exemptions in Medicare Part B ASP calculations; may reduce specialty product payments to customers and push manufacturers to alternative wholesaler contracting structures.

93%
Source evidence
“The final rule would, among other things, tighten the standards for the BFSF exemptions by requiring certifications that fee recipients will not pass fees through to downstream customers or clients”

EU pharmaceutical price controls and HTA Regulation 2021/2282

EU: government price controls and reference pricing at launch; EU HTA Regulation 2021/2282 applicable 1/12/2025 with joint clinical assessments influencing national reimbursement; pressure on pricing may reduce purchases or force price cuts.

92%
Source evidence
“The new EU Health Technology Assessment (HTA) Regulation 2021/2282 became applicable on January 12, 2025 and aims at harmonizing HTA processes across EU member states”

Opioid-related regulatory scrutiny of distribution

Opioid scrutiny: investigations/litigation and proposed legislation limiting prescriptions and tightening distribution monitoring; DQSA/DSCSA compliance failures could suspend or delay distribution and raise costs.

90%
Source evidence
“federal, state and local governmental and regulatory agencies are considering legislation and regulatory measures to limit opioid prescriptions and more closely monitor distribution, prescribing, and dispensing of these drugs”

Medicaid rebate ceiling removal effective January 1, 2024

Medicaid rebate ceiling removed effective 1/1/2024; has driven WAC price reductions and changed manufacturer price increases for certain products.

90%
Source evidence
“the removal of the ceiling on manufacturer Medicaid rebate amounts, effective January 1, 2024, has led to WAC price reductions and affected manufacturer price increases for certain products”

Changes to COVID-19 vaccination policies

Limitations on COVID-19 vaccinations and pediatric schedule changes may reduce availability/access to distributed vaccine products.

85%
Source evidence
“recent limitations on COVID-19 vaccinations and changes to pediatric vaccination schedules may have an adverse impact on the availability or access to certain products that we distribute”

IRA Medicare drug pricing reforms

IRA: Medicare price negotiation ('maximum fair prices') starts 2026 (Part D) and 2028 (Part B); inflation rebates, insulin cost-sharing limits, Part D redesign; may impact customer pricing, distribution relationships, and drug prices.

97%
Source evidence
“federal price negotiation of "maximum fair prices" for certain "selected" high-expenditure drugs under Medicare Parts D and B, applicable beginning in 2026 for Part D drugs and 2028 for Part B drugs”

Customer/GPO contract renewal risk

Key customer/GPO contracts subject to annual expiration; loss could materially affect results

95%
Source evidence
“A number of our contracts with key customers or GPOs are typically subject to expiration each year, and we may lose any of these customers or GPO relationships if we are unable to extend, renew, renegotiate or replace such expired contracts.”

Third-party cybersecurity risk in supply chain

Heavy supply-chain dependence means a cybersecurity incident at a supplier/subcontractor/third-party partner could significantly disrupt operations; mitigated via monitoring tools, questionnaires, audits, and contractual security addenda.

92%
Source evidence
“We heavily depend on our supply chain to provide our products and services to customers, and a cybersecurity incident involving a supplier, subcontractor, or other service provider or third-party business partner could significantly affect us”

ACA premium subsidies expiration end of 2025

ACA premium subsidies expire end of 2025; non-renewal may increase premiums/loss of coverage, increase uncompensated care, and reduce demand for products and services.

92%
Source evidence
“current federal ACA premium subsidies are set to expire at the end of 2025 which, unless renewed, may contribute to increased premiums and/or loss of healthcare insurance coverage”

Evolving AI regulation including EU AI Act

EU AI Act and expanding U.S. AI regulations (healthcare-focused) impose obligations and fines; raise compliance costs and may change operations, products and services.

90%
Source evidence
“the EU's Artificial Intelligence Act imposes requirements on AI system providers, importers, distributors, and users, as well as on general-purpose AI systems. Non-compliance may be subject to fines”

Reputational and ESG/corporate responsibility regulatory exposure

Reputation risk from negative publicity (incl. social media); growing compliance obligations from EU CSRD and CSDD and sustainability disclosures increase costs and investment.

88%
Source evidence
“including the Corporate Sustainability Reporting Directive and the Corporate Sustainability Due Diligence Directive in the EU”

Material exposure graph

Walgreens Boots Alliance
Customer Exposure

Walgreens and Boots together accounted for ~25% of fiscal 2025 revenue and ~38% of accounts receivable; Cencora is the primary distributor for Walgreens in the U.S. and Boots in the U.K.

Relevance 95·Dependency 90·Confidence 98
Source evidence
“Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025 and, as of September 30, 2025, accounted for approximately 38% of our accounts receivable, net.”
GLP-1 class products
Demand Driver

GLP-1 diabetes/weight loss products were a major revenue growth driver, adding $7.7B (+26.9%) in FY2025, though at lower gross margins.

Relevance 92·Dependency 70·Confidence 97
Source evidence
“increased sales of products labeled for diabetes and/or weight loss in the GLP-1 class of $7.7 billion, or 26.9%.”
Inflation Reduction Act (IRA)
Regulatory Exposure

IRA Medicare pricing reforms may impact customer pricing structures, manufacturer distribution relationships, revenue, billing/reimbursement, and drug prices generally.

Relevance 92·Dependency 70·Confidence 96
Source evidence
“these changes may impact our customer pricing structures, our manufacturer distribution relationships and revenue”
Health systems and physician practices (specialty products)
Customer Exposure

Growth was driven by increased sales of specialty products to health systems and physician practices; loss of an oncology customer contract terminated June 2025.

Relevance 88·Dependency 75·Confidence 90
Source evidence
“increased sales of specialty products to health systems and physician practices”
Pharmaceutical and biotech manufacturers
Supplier Dependency

Cencora distributes products sourced from pharmaceutical and biotech manufacturers and provides them with commercialization and consulting services; growth depends on manufacturer R&D output.

Relevance 85·Dependency 80·Confidence 90
Source evidence
“ongoing research and development expenditures by the leading pharmaceutical manufacturers will contribute to continued growth of the industry”
Evernorth Health Services
Customer Exposure

Evernorth Health Services accounted for approximately 13% of fiscal 2025 revenue.

Relevance 85·Dependency 70·Confidence 97
Source evidence
“Evernorth Health Services accounted for approximately 13% of our revenue in fiscal 2025.”
340B drug discount program
Regulatory Exposure

Manufacturer initiatives limiting contract pharmacy arrangements and declining to honor 340B discounted pricing/chargebacks on contract pharmacy orders directly affect Cencora's distribution of discounted drugs; state legislation adds complexity.

Relevance 85·Dependency 70·Confidence 90
Source evidence
“or direct us not to honor 340B discounted pricing requests on orders to be shipped to contract pharmacies”
CMS ASP/bona fide service fee final rule (October 2025)
Regulatory Exposure

Tightened BFSF standards could reduce Part B payments to provider customers and push manufacturers to alternative wholesaler fee structures, especially affecting physician specialty network organizations recently invested in or acquired.

Relevance 85·Dependency 65·Confidence 92
Source evidence
“These changes could result in reduced Part B payments for specialty products to our customers, and some manufacturers may seek to implement alternative pricing or contracting structures”
Medicare Part B-reimbursed providers (hospitals, oncology/retina physician practices)
Customer Exposure

Cencora sells specialty drugs to hospitals and specialty community physician practices reimbursed under Medicare Part B; CMS payment changes (340B refund recapture, ASP/BFSF rule) directly affect these customers' economics and demand.

Relevance 85·Dependency 65·Confidence 90
Source evidence
“reducing Medicare payments to all hospitals for other hospital outpatient services by 0.5% for calendar years 2026-2040”
Third-party cybersecurity risk
Regulatory Exposure

A cybersecurity incident at a supplier, subcontractor, or other third-party business partner could significantly disrupt Cencora's operations given heavy supply-chain dependence.

Relevance 85·Dependency 60·Confidence 92
Source evidence
“a cybersecurity incident involving a supplier, subcontractor, or other service provider or third-party business partner could significantly affect us”
Generics and biosimilars
Demand Driver

Generic and biosimilar usage is a favorable trend offering greater gross profit margin opportunity than brand products, though lower prices reduce revenue growth.

Relevance 80·Dependency 70·Confidence 93
Source evidence
“We consider the increase in generic and biosimilar usage a favorable trend because generic and biosimilar pharmaceuticals have historically provided us with a greater gross profit margin opportunity than brand-name products, although their lower prices reduce revenue growth.”
One Big Beautiful Bill Act (OBBBA, July 2025)
Regulatory Exposure

OBBBA Medicaid work requirements, Medicare provider payment cuts, and tightened ACA subsidy eligibility may impact customer financial stability and limit coverage/payment, affecting demand.

Relevance 80·Dependency 55·Confidence 92
Source evidence
“These provisions may impact the financial stability of our customers, and may limit coverage or payment, and therefore affect demand, for our products and services”
Sycamore Partners (WBA owner)
Customer Exposure

WBA's new private equity owner may seek changes to operations or the relationship that could affect distribution agreements with Walgreens, WBAD, and Boots, including possible acceleration of ~1,200 U.S. store closures.

Relevance 75·Dependency 65·Confidence 95
Source evidence
“In light of the reorganization of WBA and its subsidiaries into distinct business units by WBA’s new owners, such new owners may seek changes to WBA’s operations or our relationship with WBA that could affect our agreements with Walgreens, WBAD, and/or Boots.”
Aging population
Demand Driver

U.S. population aged 65+ expected at ~71 million by 2029; this group has more chronic illness and accounts for a substantial portion of healthcare expenditures, driving pharma demand.

Relevance 75·Dependency 60·Confidence 93
Source evidence
“The number of individuals aged 65 and over in the U.S. is expected to be approximately 71 million by 2029 and is the most rapidly growing segment of the population.”
Medicaid reimbursement and rebate policies
Regulatory Exposure

Reductions in Medicaid reimbursement to customers or changes to manufacturer rebate liabilities may indirectly impact prices Cencora can charge for multiple source pharmaceuticals and cause profitability declines.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“Any reduction in the Medicaid reimbursement rates to our customers or changes affecting manufacturer rebate liabilities may indirectly impact the prices that we can charge our customers”
Drug utilization and patent expirations
Demand Driver

Future revenue growth depends on drug utilization (GLP-1s), new brand therapies/vaccines, and increased generics/biosimilars from patent expirations.

Relevance 72·Dependency 50·Confidence 85
Source evidence
“the likely increase in the number of generic drugs and biosimilars that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers and the rate of conversion from brand products to those generic drugs and biosimilars”
Brand/generic price inflation and deflation
Cost Driver

LIFO provision is affected by manufacturer pricing practices; higher generic deflation increased the LIFO credit, while brand inflation and price deflation/inflation trends affect revenue growth.

Relevance 70·Dependency 55·Confidence 88
Source evidence
“The LIFO credit in fiscal 2025 was higher than the LIFO credit in fiscal 2024 primarily due to higher generic pharmaceutical deflation, offset in part by slightly higher brand pharmaceutical inflation.”
Full company information
Latest profile, trading, valuation, and identifier data stored for COR.
Share price
$339.76
Market cap
$64.85B
Exchange
NYSE
Currency
USD
CEO
Robert Mauch
Employees
49,000
IPO date
04/04/1995
Beta
0.581
Last dividend
$0.00
Day range
$334.31 – $342.09
52-week range
$244.82 – $377.54
1-day performance
0.57%
1-year performance
38.78%
Current drawdown (1Y)
-10.01%
CIK
0001140859
CUSIP
03073E105
ISIN
US03073E1055
Created
07/12/2025, 03:24:52
Last update
03/11/2026, 18:34:33

Track Cencora, Inc. with an AI analyst

See which prediction-market events move COR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to COR from your Railway `news_articles` table.

Cencora's Specialty Supply Chain: Where COR's Growth Is Headed

Zacks Investment Research • STOCK • 05/06/2026, 17:16:16

Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know

Zacks Investment Research • STOCK • 05/06/2026, 12:57:20

Cencora (NYSE: COR) Insider Buying Amidst Investigation and Stock Volatility

Market Data • Market Data • 28/05/2026, 23:12:43

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire • STOCK • 28/05/2026, 12:21:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

GlobeNewsWire • STOCK • 26/05/2026, 19:43:00

Cencora revises forecast for 2026, approves $2 billion share buyback

Reuters • STOCK • 21/05/2026, 19:13:22

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire • STOCK • 21/05/2026, 17:33:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

GlobeNewsWire • STOCK • 19/05/2026, 19:29:00

COR Investors Have Opportunity to Join Cencora, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewsWire • STOCK • 18/05/2026, 16:53:00

Rosen Law Firm Encourages Cencora, Inc. Investors to Inquire About Securities Class Action Investigation – COR

Business Wire • STOCK • 15/05/2026, 21:20:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc. - COR

PRNewsWire • STOCK • 15/05/2026, 00:25:00

Cencora, Inc. (COR) Presents at BofA Securities 2026 China Conference Transcript

Seeking Alpha • STOCK • 13/05/2026, 15:20:47